Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Maridebart Cafraglutide

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SW

Amgen · Phase 3 · Recruiting · Enrollment 300

NCT07575399

ArmPopulationDoseWeeksEstimandWeight change
MariTide Arm 1Obesity or overweightn/rn/rn/rn/r
MariTide Arm 2Obesity or overweightn/rn/rn/rn/r